Pages that link to "Q37723543"

The following pages link to Therapy of MS. (Q37723543):

Displaying 45 items.

• Population-wide principal component-based quantification of blood–brain-barrier dynamics in multiple sclerosis (Q24632212) (← links)
• Hematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality? (Q28071992) (← links)
• Nano-Drugs Based on Nano Sterically Stabilized Liposomes for the Treatment of Inflammatory Neurodegenerative Diseases (Q28546214) (← links)
• Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis (Q28740839) (← links)
• A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon (Q31037459) (← links)
• "Cure" for multiple sclerosis (MS)-Evolving views of therapy goals in patients on different stages of the disease: A pilot study in a cohort of Polish MS patients (Q33810097) (← links)
• Fingolimod and cardiac risk: latest findings and clinical implications (Q33949504) (← links)
• Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved (Q34153221) (← links)
• Effects of IFN-B on TRAIL and Decoy Receptor Expression in Different Immune Cell Populations from MS Patients with Distinct Disease Subtypes (Q34496935) (← links)
• Immunohistochemical evaluation of cell proliferation and apoptosis markers in ovarian surface epithelial cells of cladribine-treated rats (Q34560328) (← links)
• Identification of the synthetic cannabinoid R( )WIN55,212-2 as a novel regulator of IFN regulatory factor 3 activation and IFN-beta expression: relevance to therapeutic effects in models of multiple sclerosis (Q34695691) (← links)
• Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells (Q35568777) (← links)
• Sex-related factors in multiple sclerosis susceptibility and progression (Q35619427) (← links)
• The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis (Q35959784) (← links)
• The synthetic cannabinoid R( )WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α. (Q36127141) (← links)
• Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance (Q36298955) (← links)
• Interferon-β Modulates Inflammatory Response in Cerebral Ischemia (Q36877674) (← links)
• MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients (Q37139127) (← links)
• Health insurance affects the use of disease-modifying therapy in multiple sclerosis. (Q37158954) (← links)
• Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients. (Q37367956) (← links)
• The impact of gait disability on the calibration of accelerometer output in adults with multiple sclerosis (Q37442089) (← links)
• Teriflunomide and its mechanism of action in multiple sclerosis (Q37730005) (← links)
• Immunomodulatory drug treatment in multiple sclerosis (Q37785554) (← links)
• γδ T cells and multiple sclerosis: Friends, foes, or both? (Q37825060) (← links)
• Biotherapeutic Bioanalysis: A Multi-Indication Case Study Review (Q37854629) (← links)
• Molecular recognition theory and sense-antisense interaction therapeutic applications in autoimmunity (Q37971706) (← links)
• Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review (Q38097527) (← links)
• Recent progress in omics-driven analysis of MS to unravel pathological mechanisms (Q38140023) (← links)
• Initial immunopathogenesis of multiple sclerosis: innate immune response. (Q38156767) (← links)
• Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis. (Q38639337) (← links)
• Feasibility and toxicity of hematopoietic stem cell transplant in multiple sclerosis. (Q40041536) (← links)
• Type I interferons in the pathogenesis and treatment of canine diseases (Q40045770) (← links)
• Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience (Q45155454) (← links)
• Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis--a prospective, non-randomized pilot study. (Q45912924) (← links)
• Nicotine Augments the Beneficial Effects of Mesenchymal Stem Cell-based Therapy in Rat Model of Multiple Sclerosis. (Q46944384) (← links)
• Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12. (Q47698731) (← links)
• Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs. (Q48068722) (← links)
• Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation (Q48460923) (← links)
• The direct cost of patients with multiple sclerosis: a survey from Italian MS centres (Q50109451) (← links)
• Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood (Q51025796) (← links)
• Synergistic effects of atorvastatin and all-trans retinoic acid in ameliorating animal model of multiple sclerosis. (Q51201110) (← links)
• Direct modulation of myelin-autoreactive CD4 and CD8 T cells in EAE mice by a tolerogenic nanoparticle co-carrying myelin peptide-loaded major histocompatibility complexes, CD47 and multiple regulatory molecules. (Q55442040) (← links)
• Intrinsic apoptosis pathway in fallopian tube epithelial cells induced by cladribine. (Q55497215) (← links)
• Rationing and deprivation: disease-modifying therapies for multiple sclerosis in the United Kingdom (Q57573402) (← links)
• Comparison of the effects of 17β- estradiol treated and untreated mesenchymal stem cells on ameliorating animal model of multiple sclerosis. (Q64966459) (← links)